WuXi Junuo Announces Its Cellular Immunotherapy Drug Has Successfully Benefited 200 Chinese Patients
Time of Update: 2022-05-16
>. Benoda® is currently the only CAR- T cell immunotherapy product in China that has received three awards at the same time, including the "Major New Drug Creation
Bring more benefits to liver cancer patients!
Time of Update: 2022-05-16
Early stage patients: resection is still the preferred treatment method For the treatment of liver cancer, Professor Xing Baocai once put forward the concept of "organically combining oncology and surgery, and striving to maximize the benefit of patients" .
China expands pangasius imports, Vietnamese exporters benefit
Time of Update: 2022-05-14
imported frozen fish China's imports of pangasius suddenly increased to 12,800 tonnes in February this year, exceeding the level of imports from 2019 to February 2021 .
Ovarian cancer treatment enters the era of precision treatment Expert: targeted drugs benefit patients
Time of Update: 2022-05-14
The reporter learned on the 8th that both newly diagnosed ovarian cancer patients and platinum-sensitive recurrence patients can benefit from targeted drugs-PARP inhibitors, which greatly prolong the disease progression-free survival period and bring "clinical" to many patients.
Western countries impose sanctions on Russia, which may benefit Vietnamese seafood exports
Time of Update: 2022-05-14
. In addition to concerns about sanctions, the biggest concern is that retailers will follow public opinion and boycott products from Russia. After
China's insulin centralized procurement implements "high quality and reasonable price" drugs to benefit a large number of diabetic patients
Time of Update: 2022-05-13
Measures for the Centralized Procurement and Use of Nationally Organized Drugs (Insulin Special)" . The reporter learned on the 5th that the average price of the drugs selected for the insulin
JCEM: Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in patients with type 2 diabetes
Time of Update: 2022-05-11
Empagliflozin may be the treatment of choice in patients with type 2 diabetes at risk for cardiovascular disease; its cardiovascular benefits may be related to changes in gut microbiota and plasma metabolites .
Policies continue to benefit the traditional Chinese medicine industry. How to grasp the main line of future development?
Time of Update: 2022-05-09
that the "14th Five-Year Plan" for the development of traditional Chinese medicine takes into account the key areas of traditional Chinese medicine development such as medical treatment, scientific research, industry, education, culture, and international
The benefits of the PNAS movement can vary widely
Time of Update: 2022-05-08
of developing secondary metabolic diseases such as diabetes or neurodegenerative diseases . >However, these recommendations are based on healthy people without primary mitochondrial disease
Pharmaceutical companies are strengthening domestic substitution of upstream equipment, and the pharmaceutical machine industry may benefit
Time of Update: 2022-05-02
Recently, Kangfang Bio announced that it has reached a cooperation with Shanghai Duoning Biotechnology Co.
, Ltd
, Ltd
Traditional Chinese medicine innovation, and then welcome heavy benefits!
Time of Update: 2022-05-02
In recent years, in order to encourage the innovation of traditional Chinese medicine and promote the development
Sprinting for the first-line treatment of urothelial carcinoma, the survival benefit of PD-L1
Time of Update: 2022-05-02
February 22, 2022 / eMedClub News / -- Urothelial carcinoma (UC) is a relatively common type of advanced urinary tumors
-
-
-
-
-
-
-
The innovation of traditional Chinese medicine has ushered in continuous benefits
Time of Update: 2022-05-02
In order to encourage the innovation of traditional Chinese medicine and promote the development of traditional Chinese
Dupixent, which is expected to benefit infants and young children with eczema, has been granted priority review
Time of Update: 2022-05-02
On February 10, 2022, Regeneron and Sanofi announced that the U.
S.
FDA has granted priority review
announced, and the industry leaders responded positively, improving quality and reducing prices for the benefit of the people!
Time of Update: 2022-04-30
River Delta Alliance with Shanghai, Zhejiang and Anhui as the main body "wins its first battle" . > Reducing the price of good medicines, reducing the pressure of medical insurance
How will intensive and stable blood pressure lowering benefit patients with cerebral hemorrhage?
Time of Update: 2022-04-29
to take oral drugs, intravenous preparations should be preferred, and blood pressure should be closely monitored during treatment to protect target organs . In general, it is necessary
Powerful hypoglycemic benefits, the new GLP-1RA weekly preparation program helps T2DM patients to comprehensively improve blood sugar and metabolic indicators
Time of Update: 2022-04-29
In addition, for patients with type 2 diabetes who do not have ASCVD or high risk factors for ASCVD, injectable drugs, such as GLP-1RA and insulin, can be used in combination with metformin treatment to further control blood sugar[1,5] .
Professor Feng Ru: PI3K Inhibitors Help FL and MZL "No Chemotherapy", Bringing Survival Benefits to Patients
Time of Update: 2022-04-29
The SAKK 35/10 phase II study showed that the R2 regimen had an overall response rate (ORR) of 81% and a median PFS of 5 years, which was superior to rituximab monotherapy .
The traditional Chinese medicine industry has ushered in a period of opportunity, and a large number of enterprises will benefit
Time of Update: 2022-04-28
The industry expects that in the next few years, benefiting from the successive implementation of favorable policies in the Chinese medicine sector, the Chinese medicine industry will usher in a period of development opportunities .
Welcome to ECHEMI